Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MIV tests SagaX' embolic protection technology

This article was originally published in Clinica

Executive Summary

MIV Therapeutics is beginning animal trials of an embolic protection device for catching blood clots that become dislodged during cardiac procedures and can travel to the brain and cause a stroke. The aortic embolic protection device (AEPD) was developed by SagaX Medical Technologies, a company recently acquired by MIV (see Clinica No 1150, p 14). The AEPD, which is placed in a main artery, is designed for use during invasive heart procedures such as electrophysiology, valve dilatations and valve repair through angioplasty. The technology may also find broad preventative application during minimally invasive alternatives to open surgery, said Vancouver, British Columbia-based MIV, which estimates the product's market to exceed $1.5-1.8bn by 2009.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT055167

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel